secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001438533-23-000023
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks
---------------------------------------------------------------

- Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).
- Cash $561.5M after $216M stock offering and $23M milestone to Ligand for FILSPARI approval.
- FILSPARI launched week of Feb 27; 146 new patient start forms received in first 6 weeks.
- Phase 3 DUPLEX in FSGS missed primary eGFR slope endpoint; company to engage regulators on path forward.
- EMA decision on sparsentan for IgAN expected H2 2023; PROTECT confirmatory data due Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/0001438533-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000023/tvtx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer